Get the Stockscreener App
40.62
5.37%
2.07
After Hours:
41.27
0.65
+1.60%
Guardant Health Inc stock is traded at $40.62, with a volume of 2.50M.
It is up +5.37% in the last 24 hours and down -17.99% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$38.55
Open:
$38.31
24h Volume:
2.50M
Relative Volume:
1.20
Market Cap:
$5.03B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-9.5802
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+6.89%
1M Performance:
-17.99%
6M Performance:
+14.07%
1Y Performance:
+47.87%
1-Day Range:
$38.07
$41.15
1-Week Range:
$37.73
$41.15
52-Week Range:
$20.14
$52.92
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
40.62 | 4.71B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - Insider Monkey
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti - GuruFocus
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus
Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus
How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals
Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Nuveen Asset Management LLC - Defense World
Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com South Africa
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart L - GuruFocus
Guardant Health enhances cancer blood test capabilities - Investing.com
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune
Ameriprise Financial Inc. Purchases 76,124 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
New Tests Promise to Reveal the Secrets in Your Blood - WSJ
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace
(GH) Technical Data - news.stocktradersdaily.com
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio - Insider Monkey
Guardant Health Launches Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - BioSpace
Guardant Health, Inc. Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors | GH Stock News - GuruFocus
Guardant Health expands oncology testing with IHC suite - Investing.com
Guardant Health unveils new cancer risk test By Investing.com - Investing.com South Africa
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer - BioSpace
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer | GH Stock News - GuruFocus
Guardant Health unveils new cancer risk test - Investing.com
Guardant Health: A Promising Player in the Liquid Biopsy Market - The Globe and Mail
Guardant Health: A Promising Player In The Liquid Biopsy Market - Barchart.com
New Horizons in Cancer Genetic Profiling Market Exploring - openPR.com
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Transcript : Guardant Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum - Yahoo Finance
How to Take Advantage of moves in (GH) - news.stocktradersdaily.com
Guardant Health to Participate in Upcoming Investor ConferencesMay 8, 2025 - BioSpace
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year - 01net
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List o - GuruFocus
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):